Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hyperfine Inc (HYPR)

Hyperfine Inc (HYPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Horizon Technology Finance Provides $40 Million Loan Facility to Hyperfine

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $40 million loan facility to Hyperfine, Inc....

HYPR : 1.0800 (+4.85%)
HRZN : 4.23 (+3.42%)
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the...

HYPR : 1.0800 (+4.85%)
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop®...

HYPR : 1.0800 (+4.85%)
Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities

The largest dataset to date on stroke detection with the Swoop® system demonstrates the ability to identify small strokes rapidly and reliably, reinforcing its clinical value for acute care and emergency...

HYPR : 1.0800 (+4.85%)
Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics

Data presented at the annual American Society of Neuroimaging meeting supports clinical value and broad utility of the portable Swoop® system in outpatient neurology.

HYPR : 1.0800 (+4.85%)
Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents

The prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI to support an FDA 510(k) submission.

HYPR : 1.0800 (+4.85%)
Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative Growth of 54% Compared to Prior Quarter; Exiting 2025 with Approximately $35 Million of...

HYPR : 1.0800 (+4.85%)
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

HYPR : 1.0800 (+4.85%)
OFIX : 11.47 (+1.33%)
SPNC : 38.45 (unch)
AVNS : 14.02 (+2.11%)
PLSE : 21.52 (+9.63%)
SWAV : 334.75 (-0.02%)
Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today...

HYPR : 1.0800 (+4.85%)
Hyperfine Announces Regulatory Approval of the Swoop® System in India

India's Central Drugs Standard Control Organization (CDSCO) has approved the Hyperfine Swoop system, opening a major global market. Commercial launch to begin early 2026.

HYPR : 1.0800 (+4.85%)

Barchart Exclusives

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.